(GEHC) GE HealthCare Technologies - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 28.872m USD | Total Return: -16.5% in 12m
Medical Imaging, Ultrasound, Patient Monitoring, Contrast Media, Anesthesia
Total Rating 37
Safety 71
Buy Signal -0.96
Medical Devices
Industry Rotation: +6.2
Industry Rotation: +6.2
Market Cap:
28.9B
Avg Turnover: 310M
Avg Turnover: 310M
Risk 3d forecast
Volatility37.2%
VaR 5th Pctl6.12%
VaR vs Median-0.17%
Reward TTM
Sharpe Ratio-0.54
Rel. Str. IBD10.3
Rel. Str. Peer Group24
Character TTM
Beta1.292
Beta Downside1.396
Hurst Exponent0.555
Drawdowns 3y
Max DD37.35%
CAGR/Max DD-0.23
CAGR/Mean DD-0.60
EPS (Earnings per Share)
EPS CAGR: -15.96%
EPS Trend: -14.3%
EPS Trend: -14.3%
Last SUE: -0.48
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 3.66%
Rev. Trend: 51.6%
Rev. Trend: 51.6%
Last SUE: 1.19
Qual. Beats: 2
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: GEHC GE HealthCare Technologies
GE HealthCare Technologies Inc. (GEHC) is a global medical technology company specializing in diagnostic imaging, patient monitoring, and pharmaceutical diagnostics. The company operates through four primary segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Its portfolio encompasses a wide range of hardware and digital solutions, including MRI and CT scanners, ultrasound systems, patient monitoring devices, and contrast media used in nuclear medicine.
The medical technology sector is characterized by high barriers to entry due to significant research and development costs and rigorous regulatory approval processes. GEHC follows a diversified business model that combines capital equipment sales with recurring revenue streams from consumables, maintenance services, and integrated digital software solutions. Investors can evaluate the company’s long-term valuation metrics by visiting ValueRay.
- Aging global population increases demand for high-end diagnostic imaging and molecular tracers
- Expansion of precision medicine and AI-integrated digital solutions improves long-term profit margins
- Strategic contrast media supply chain investments mitigate pharmaceutical diagnostic segment supply risks
- Hospital capital expenditure cycles and reimbursement rate changes impact medical equipment order volume
Piotroski VR‑10 (Strict)
5.0
| Net Income: 1.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.00 > 1.0 |
| NWC/Revenue: 7.28% < 20% (prev -3.00%; Δ 10.27% < -1%) |
| CFO/TA 0.05 > 3% & CFO 2.03b > Net Income 1.50b |
| Net Debt (8.29b) to EBITDA (3.17b): 2.61 < 3 |
| Current Ratio: 1.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (457.0m) vs 12m ago -0.44% < -2% |
| Gross Margin: 42.55% > 18% (prev 0.42%; Δ 4.21k% > 0.5%) |
| Asset Turnover: 56.44% > 50% (prev 58.95%; Δ -2.51% > 0%) |
| Interest Coverage Ratio: 4.13 > 6 (EBITDA TTM 3.17b / Interest Expense TTM 435.0m) |
Altman Z''
1.27
| A: 0.04 (Total Current Assets 9.98b - Total Current Liabilities 8.53b) / Total Assets 37.12b |
| B: 0.15 (Retained Earnings 5.65b / Total Assets 37.12b) |
| C: 0.05 (EBIT TTM 1.80b / Avg Total Assets 35.36b) |
| D: 0.16 (Book Value of Equity 4.26b / Total Liabilities 26.23b) |
| Altman-Z'' Score: 1.27 = BB |
Beneish M
-2.97
| DSRI: 1.08 (Receivables 4.74b/4.35b, Revenue 19.95b/19.80b) |
| GMI: 0.99 (GM 42.55% / 41.99%) |
| AQI: 1.02 (AQ_t 0.65 / AQ_t-1 0.64) |
| SGI: 1.01 (Revenue 19.95b / 19.80b) |
| TATA: -0.01 (NI 1.50b - CFO 2.03b) / TA 37.12b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of GEHC shares?
As of May 17, 2026, the stock is trading at USD 60.76 with a total of 4,775,601 shares traded.
Over the past week, the price has changed by -4.27%, over one month by -17.34%, over three months by -25.51% and over the past year by -16.51%.
Over the past week, the price has changed by -4.27%, over one month by -17.34%, over three months by -25.51% and over the past year by -16.51%.
Is GEHC a buy, sell or hold?
GE HealthCare Technologies has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy GEHC.
- StrongBuy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GEHC price?
| Analysts Target Price | 80 | 31.6% |
GE HealthCare Technologies (GEHC) - Fundamental Data Overview
as of 12 May 2026
P/E Trailing = 15.2206 P/E Forward = 12.9534
P/S = 1.3762
P/B = 2.7064
P/EG = 1.7866
Revenue TTM = 19.95b USD
EBIT TTM = 1.80b USD
EBITDA TTM = 3.17b USD
Long Term Debt = 10.13b USD (from longTermDebt, last quarter)
Short Term Debt = 139.0m USD (from shortTermDebt, last quarter)
Debt = 10.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.29b USD (from netDebt column, last quarter)
Enterprise Value = 37.16b USD (28.87b + Debt 10.58b - CCE 2.29b)
Interest Coverage Ratio = 4.13 (Ebit TTM 1.80b / Interest Expense TTM 435.0m)
EV/FCF = 24.45x (Enterprise Value 37.16b / FCF TTM 1.52b)
FCF Yield = 4.09% (FCF TTM 1.52b / Enterprise Value 37.16b)
FCF Margin = 7.62% (FCF TTM 1.52b / Revenue TTM 19.95b)
Net Margin = 7.54% (Net Income TTM 1.50b / Revenue TTM 19.95b)
Gross Margin = 42.55% ((Revenue TTM 19.95b - Cost of Revenue TTM 11.46b) / Revenue TTM)
Gross Margin QoQ = 38.53% (prev 54.34%)
Tobins Q-Ratio = 1.00 (Enterprise Value 37.16b / Total Assets 37.12b)
Interest Expense / Debt = 0.91% (Interest Expense 96.0m / Debt 10.58b)
Taxrate = 18.61% (94.0m / 505.0m)
NOPAT = 1.46b (EBIT 1.80b * (1 - 18.61%))
Current Ratio = 1.17 (Total Current Assets 9.98b / Total Current Liabilities 8.53b)
Debt / Equity = 0.99 (Debt 10.58b / totalStockholderEquity, last quarter 10.67b)
Debt / EBITDA = 2.61 (Net Debt 8.29b / EBITDA 3.17b)
Debt / FCF = 5.46 (Net Debt 8.29b / FCF TTM 1.52b)
Total Stockholder Equity = 10.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.26% (Net Income 1.50b / Total Assets 37.12b)
RoE = 14.77% (Net Income TTM 1.50b / Total Stockholder Equity 10.19b)
RoCE = 8.85% (EBIT 1.80b / Capital Employed (Equity 10.19b + L.T.Debt 10.13b))
RoIC = 7.18% (NOPAT 1.46b / Invested Capital 20.36b)
WACC = 7.90% (E(28.87b)/V(39.45b) * Re(10.53%) + D(10.58b)/V(39.45b) * Rd(0.91%) * (1-Tc(0.19)))
Discount Rate = 10.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -18.16 | Cagr: -0.10%
[DCF] Terminal Value 78.39% ; FCFF base≈1.46b ; Y1≈1.42b ; Y5≈1.42b
[DCF] Fair Price = 38.86 (EV 25.97b - Net Debt 8.29b = Equity 17.68b / Shares 454.9m; r=7.90% [WACC]; 5y FCF grow -4.08% → 3.0% )
EPS Correlation: -14.30 | EPS CAGR: -15.96% | SUE: -0.48 | # QB: 0
Revenue Correlation: 51.62 | Revenue CAGR: 3.66% | SUE: 1.19 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.04 | Chg30d=-10.91% | Revisions=-68% | Analysts=15
EPS next Quarter (2026-09-30): EPS=1.25 | Chg30d=-0.94% | Revisions=-6% | Analysts=15
EPS current Year (2026-12-31): EPS=4.88 | Chg30d=-3.37% | Revisions=-73% | GrowthEPS=+6.4% | GrowthRev=+5.6%
EPS next Year (2027-12-31): EPS=5.38 | Chg30d=-3.34% | Revisions=-64% | GrowthEPS=+10.2% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -73%